Skip to content
ClinCalc Pro
Menu
cardiology

GARFIELD-AF Risk Score for Atrial Fibrillation

Risk model from the Global Anticoagulant Registry in the FIELD-AF study. Predicts 1-year risk of stroke/SE, major bleeding, and all-cause mortality in newly diagnosed non-valvular AF. Adds smoking and renal function to traditional CHA2DS2-VASc variables.

Used in: Atrial Fibrillation

Score interpretation

Low Risk 0–1

Low GARFIELD-AF score — lower 1-year event risk

→ CHA2DS2-VASc guided anticoagulation; if score under 2 (men) or under 3 (women): anticoagulation not routinely recommended; lifestyle modification; rate control if symptomatic; annual reassessment

Moderate Risk 2–4

Moderate score — significant thromboembolic risk

→ DOAC initiation (per NICE NG196); HAS-BLED assessment; modify reversible bleeding risks; rate or rhythm control strategy; risk factor modification; annual review

High Risk 5–12

High GARFIELD-AF score — high 1-year stroke and mortality risk

→ Initiate DOAC urgently; prior stroke: start 2 to 14 days post-event depending on infarct size; if DOAC contraindicated: warfarin INR 2 to 3; BP control; diabetes optimisation; smoking cessation; cardiology or stroke specialist input; LAA occlusion if DOAC long-term contraindicated

Interpretation bands for the GARFIELD-AF. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.